There is now little doubt that functional immune polymorphism exists and can exert a significant effect on the severity of immunologic disease. Studies in this area are driven by the belief that an understanding of the influence of immune polymorphism on immunologic disease will improve our ability to predict disease occurrence and severity. The usefulness of this information is necessarily limited, however, by the fact that an individual has a fixed genome. If an individual has an allele which predisposes to increased disease severity, there is little we can do, other than treat the disease in that individual in a more aggressive manner or attempt to find preventative therapies. There is, however, one unique immunologic disorder that is an exception to this rule. Graft-versus-host disease (GVHD), the major complication of bone marrow transplantation, is an immunologic reaction mediated, in large part, by donor T cells. It is unique in that it is the only immunologic disorder in which we can choose the genetics of the immune system causing the disorder. In this disease, more than any other, an understanding of the role of immune polymorphism is essential since we could hypothetically use this information to choose a donor whose T cells will not mediate GVHD of life-threatening severity. In this review, I argue that there is highly suggestive evidence that allelic polymorphism in non-MHC genes encoding mediators of the immune response exerts a very significant effect on the severity of GVHD and that typing for such allelic polymorphisms will in future be as important as MHC-typing in choosing an appropriate donor for bone marrow transplantation. Genes and Immunity (2000) 1, 316-320.
Introduction
It is becoming increasingly apparent that many of the genes encoding key mediators of the immune response are polymorphic. In humans, polymorphism has been identified in a wide range of genes encoding such mediators, including IL-1␣, 1 IL-1␤, 2 the IL-1 receptor antagonist, 2 IL-2, 3 IL-3, 4 IL-4, 5-7 the IL-4 receptor 8 the common ␤ subunit of the GM-CSF, IL-3 and IL-5 receptors, 9 IL-6, 10 IL-10, 11 IL-13, 12 IFN-␥, 13, 14 TNF-␣, 15 TNF-␤, 16 the TNF receptor, 17 TGF-␤, 18 22 While some of this diversity may represent random genetic variation, evidence suggests that at least some of these polymorphisms do influence the expression of the genes involved. 2, 13, 15, 20, [23] [24] [25] [26] Logically, it would be expected that these polymorphisms might therefore exert an influence on the course and severity of immunologic disease. Accumulating evidence suggests that this is indeed the case. 5, 10, 17, 22, [25] [26] [27] [28] [29] [30] This review focuses on the implications of this functional immune polymorphism for a unique immunologic disorder, graft-versushost disease (GVHD).
GVHD is the major complication occurring after bone marrow transplantation, resulting in significant patient mortality. It is an immunologic disorder in which donor T cells are activated by host major and minor histocompatibility antigens and subsequently lead an immunologic attack on host tissues. A singular feature of GVHD is that it is the only immunologic disease in which we can choose the source of the T cells mediating the disorder.
At present, bone marrow donors are chosen solely on the basis of the degree to which their HLA antigens match those of the bone marrow recipient. With our increasing awareness of the impact of allelic variation at functional immune loci on the severity of immunologic disease, an inevitable question is whether we should also be considering the genetic makeup of potential donors at such functional loci when choosing donors for bone marrow transplantation.
The simple answer to this question is that, since it is extremely difficult to find a donor with a complete HLA antigen match with the recipient, it would be essentially impossible to find a donor both matched for HLA antigens and also having a particular genotype at other functional loci. Therefore, there would seem to be little point in pursuing this path. Things may not be this simple, however. In this review, I argue that polymorphisms in immune effector genes may be as important as the degree of HLA antigen mismatch in determining GVHD severity and, indeed, that choosing a donor with suitable alleles at immune effector loci may allow use of donors with lower degrees of HLA antigen matching while still avoiding severe GVHD. Thus, rather than restricting the potential donor pool even further, 'immunogenotyping' may actually expand it.
Quantity vs quality of T cell activation
Antigen disparity between host and donor is certainly a requirement for GVHD to occur since GVHD is initiated when donor T cells recognize foreign antigens of the host. The severity of GVHD might be expected to broadly correspond to the degree of antigen mismatch between host and donor, as that would determine the overall quantity of T cell activation. But in drawing such simple correlations between the degree of antigen mismatch, the quantity of T cell activation and the severity of GVHD, one important factor is being left out of the equationthe quality of T cell activation. The severity of GVHD might in fact depend not only on how many T cells are being activated in response to host antigens, but also on what those T cells do after they are activated. This latter aspect might vary depending on genetic variation between donors at non-MHC loci encoding functional mediators of the immune response.
An excellent example of this is to be found in the commonly studied B6D2F1 parent→F1 murine GVHD model, shown in Figure 1 . In this model, two alternative mouse strains, C57BL/6 (B6) or DBA/2, are used as a source of donor cells to initiate GVHD in hybrid (C57BL/6 × DBA/2)F1 (ie, B6D2F1) recipients. In both cases, the GVHD is being initiated across an entire MHC mismatch, and so there should be a large quantity of T cell activation in both cases. And yet, the GVHD that develops in both cases is entirely different. If C57BL/6 donors are used, recipients develop severe, acute GVHD with significant mortality within 30 days of cell transfer, while if DBA/2 donors are used, no acute GVHD is observed and mice instead go on to develop chronic GVHD characterized by excessive B cell activation. 31 Clearly, the genetics of the donor influences the course of GVHD in this model. B10.D2 donors, which are identical to DBA/2 donors at the MHC but similar to C57BL/6 mice at non-MHC loci, behave similarly to C57BL/6 donors and induce acute GVHD. 32 This indicates that it is the non-MHC genetics of the donor that influences GVHD outcome in this model. Indeed, our studies have indicated that loci on chromosomes 1 and 2, in the vicinity of the Mtv7 and IL-1 loci respectively, influence GVHD development in the B6D2F1 model. [33] [34] [35] The differential outcome of GVHD in the B6D2F1 model is thought to be due to differential activation of Figure 1 The B6D2F1 parent→F1 murine GVHD model. In this model, transfer of parental strain C57BL/6 lymphoid cells into (C57BL/6 × DBA/2)F1 (ie, B6D2F1) recipients results in acute GVHD whereas transfer of parental strain DBA/2 lymphoid cells into B6D2F1 recipients results in chronic GVHD.
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Th1 vs Th2 helper cells in the acute and chronic GVHD situations respectively. 36 Therefore, in this model, non-MHC loci influence not the quantity of T cell activation, but rather the quality of T cell activation-whether T cells ultimately differentiate along the Th1 or Th2 pathway. This model therefore clearly demonstrates the principle that the non-MHC genetics (most likely allelic variation at loci encoding functional immune mediators) of donors can exert a powerful effect on the development of GVHD.
Further evidence that donor immune polymorphism influences GVHD severity
In 1998, Middleton et al 37 investigated whether recipient allelic polymorphism at the loci encoding TNF-␣ and IL-10 influences the severity of graft-versus-host disease occurring in patients after bone marrow transplantation. Linkage was observed between both loci and GVHD severity. This study demonstrates clearly that polymorphism in genes encoding immune mediators can potentially influence GVHD severity. Unfortunately, Middleton et al 37 did not investigate the impact of donor polymorphism at these loci, which arguably might be a more important aspect to consider since it is the donor who can be chosen.
In a murine model, Cooke et al 38 have provided evidence that the severity of GVHD can indeed be influenced by the amount of TNF-␣ produced by donor cells. Donor mice bearing a genetic mutation rendering their cells resistant to LPS were observed to induce significantly less GVHD than donor mice whose cells were responsive to LPS. Donor cells that were responsive to LPS produced high amounts of TNF-␣ and mediated severe GVHD, while donor cells that were resistant to LPS appeared to produce significantly less TNF-␣ and consequently induced significantly less severe GVHD. Considering the known polymorphisms in TNF-␣ in humans 15 and the findings of Middleton et al 37 described above, this observation that donor variation in TNF-␣ production can affect GVHD severity is intriguing.
Polymorphism of TNF-␣ and IL-10 has also been implicated as influencing the rejection of solid tissue transplants. 30, [39] [40] [41] [42] [43] In this case, variation in host genotype at the loci encoding these effector cytokines influenced graft rejection. Given this finding, it is not difficult to imagine that polymorphism at such loci might also influence GVHD.
In demonstration of the narrow focus of the field on the role of antigen in GVHD, the only other authors to consider the role of polymorphism at immune effector loci on GVHD have interpreted their findings solely in terms of how such polymorphisms might be acting as minor histocompatibility antigens rather than in terms of how such polymorphisms might alter the function of the molecules involved and thereby the course of the immune response that comprises GVHD. These studies include investigation of polymorphisms in CD2, CD31, CD42, CD49b, CD54 and CD62L. 19, 21, 44 Unfortunately, insufficient information was given in these reports to allow re-evaluation of the data in terms of the possible functional impact of the different allelic forms of these molecules.
Universal donors?
Another striking example of the influence of donor genetics on the course of GVHD is to be found in a report by Fontaine et al. 45 In a study in which they investigated GVHD severity in every possible donor-recipient combination of six MHC-matched (H-2 b ) mouse strains, an interesting pattern emerged. One strain, C57BL/6 (B6), was observed to induce severe, acute GVHD with significant mortality in all of the possible recipient strains. Conversely, another strain, C3H.SW, induced severe, acute GVHD in none of the possible recipient strains. These observations imply that the B6 strain is for some reason inherently more likely to induce severe acute GVHD than the C3H.SW strain, which behaves like a 'universal donor' in that it never appears to induce significant acute GVHD.
Two hypotheses could account for these observations. The first possibility is that there are some 'major' minor histocompatibility antigens that exert a very significant effect on GVHD development, as hypothesized by Perreault et al. 46 This explanation would require that the B6 strain differs from all of the recipient strains at such a 'major minor' antigen while the C3H.SW strain does not differ from any of the other strains at this locus.
An alternative possibility is that the severity of GVHD is being influenced by the set of alleles a donor strain possesses at specific loci encoding functional mediators of the immune response. This second hypothesis easily accounts for the observation that the behavior of B6 and C3H.SW donors is the same in a large number of recipient strains, whereas the former hypothesis would rely on an unlikely event (all of the strains expressing a 'major' minor antigen that B6 alone does not express) in order to explain this.
Further evidence in support of the second hypothesis may be found in the observation that the B6 strain is associated with efficient inflammatory responses in a variety of immunological systems. These include the B6D2F1 model described above 31 and infection with Leishmania major, 47 Ectromelia, 48 Listeria 49 and Schistosoma mansoni. 50 The fact that C57BL/6 mice make efficient, Th1-mediated responses in all of these situations suggests that this strain is 'immunologically biased' towards making Th1, inflammatory immune responses (as a result of the set of alleles it possesses at polymorphic loci encoding mediators of the immune response). As a result of this inherent bias, the B6 strain may make a poor donor for bone marrow transplantation even in an MHC-matched setting. The C3H.SW strain, on the other hand, may be immunologically less prone to severe inflammatory responses and may represent a 'universal donor' whose cells may have difficulty mediating severe acute GVHD, possibly even in a setting with some MHC-mismatch. There is no reason to believe that similar differences in 'GVHD-inducing-ability' might not be found among human bone marrow donors and that some individuals may exist who, analogous to the C3H.SW strain, are unlikely to cause significant acute GVHD in recipients.
Too many restrictions on choosing a donor?
If genetic variation at immune effector loci does indeed lead to overall bias in the likelihood that an individual donor's cells will cause more or less severe GVHD, should we investigate the possibility of incorporating 'immunogenotyping' as part of the donor selection mechanism for bone marrow transplantation? Given the difficulty already encountered in finding a suitable MHCmatched donor, it would seem to be impractical to add further requirements to donor selection. However, it should be remembered that the need for ideal MHCmatching has evolved in an atmosphere in which no consideration has been given to the effect of allelic variation at non-MHC donor loci. Certainly, when immune polymorphism is not considered at all, decreasing the quantity of T cell activation is the best thing to do and optimizing the MHC match between patient and donor is essential. However, consideration of the quality of T cell activation may relieve some of the need to decrease the quantity of activation.
An example of this principle may be seen in our recent work in the B6D2F1 model. In that model, we were able to show that the severity of GVHD in a completely MHCmismatched setting depended on the genotype of donor mice at two specific non-MHC loci-one on chromosome 1 and one on chromosome 2. 33, 34 Mice with a specific genotype at these loci had a significantly lowered risk of inducing severe acute GVHD, even though they were MHC-mismatched with recipients. 34 This indicates that it is possible to choose donors whose non-MHC genetics will reduce the risk of their cells inducing life-threatening GVHD in recipients, even when there is not a perfect MHC match. The implication of this is that, by considering donor immune polymorphism, it may be possible to actually expand the donor pool to include donors without perfect MHC matches but with favorable alleles at functional loci.
Conclusion
Despite the application of stringent procedures for ensuring the best possible MHC-matching between bone marrow donors and recipients, life-threatening, acute GVHD continues to occur. Our growing knowledge of the effects of functional immune polymorphism on immunologic disease suggests strongly that this polymorphism may exert a significant effect on the severity and course of GVHD occurring after bone marrow transplantation. Studies in murine models also support a clear and sig-nificant role for non-MHC donor polymorphism in influencing GVHD outcome.
It is time for the transplantation community to stop focusing on host-donor antigen disparity as being the only determinant of GVHD severity and begin a thorough analysis of the role of donor immune polymorphism in GVHD. By developing a knowledge of how donor allelic variation in immune effector molecules influences GVHD development, it may be possible in future to make more informed donor choices and to decrease significantly the incidence of life-threatening GVHD.
